A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

992

Enrollment

INDUSTRY

Sponsor class

Conditions

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: Giredestrant
DRUG: Giredestrant-matched Placebo
DRUG: Letrozole
DRUG: Letrozole-matched Placebo
DRUG: Palbociclib
DRUG: LHRH Agonist

Sponsor

Hoffmann-La Roche